JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Paris, H.
Right arrow Articles by Laburthe, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paris, H.
Right arrow Articles by Laburthe, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

Alpha-2 adrenoceptor in rat jejunum epithelial cells: characterization with [3H]RX821002 and distribution along the villus-crypt axis

H Paris, T Voisin, A Remaury, C Rouyer-Fessard, D Daviaud, D Langin and M Laburthe

Institut National de la Sante et de la Recherche Medicale, Institut de Physiologie, Toulouse, France.

Alpha-2 adrenergic receptivity of rat jejunum epithelial cells was studied using the new antagonist radioligand, [3H]RX821002 [( 3H]-2-(2- methoxy-1,4-benzodioxan-2-yl)-2-imidazoline). All the parameters of [3H]RX821002 binding were consistent with the labeling of an alpha-2 adrenoceptor. The use of this probe was moreover extremely convenient, because contrarily to [3H]yohimbine and [3H]rauwolscine, [3H]RX821002 displayed in this tissue a very high affinity (Kd = 0.54 +/- 0.12 nM) and a low level of nonspecific binding (5% at 1 nM [3H]RX821002). Competition studies with various antagonists and agonists showed that the labeled sites were alpha-2-selective and stereospecific. Oxymetazoline was much more potent than chlorpromazine or prazosin suggesting that the receptor is of the alpha-2-subtype. Yohimbine and rauwolscine were equipotent, which is also in agreement with the pharmacological definition of this subtype. These two compounds displayed, however, a rather weak affinity (Ki approximately 40 nM), which is somewhat different with what one should expect for a true alpha-2A adrenoceptor. Altogether the competition data indicated that the alpha-2 adrenoceptor from rat jejunal epithelium is neither an alpha-2A, nor an alpha-2B, nor an alpha-2c adrenoceptor and may belong to a fourth subtype.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 254, Issue 3, pp. 888-893, 09/01/1990
Copyright © 1990 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
F. Berlioz, J.-J. Maoret, H. Paris, M. Laburthe, R. Farinotti, and C. Rozé
alpha 2-Adrenergic Receptors Stimulate Oligopeptide Transport in a Human Intestinal Cell Line
J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 466 - 472.
[Abstract] [Full Text]


Home page
GutHome page
S Schaak, D Cussac, C Cayla, J C Devedjian, R Guyot, H Paris, and C Denis
Alpha2 adrenoceptors regulate proliferation of human intestinal epithelial cells
Gut, August 1, 2000; 47(2): 242 - 250.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. T. Skowronski, Y. Ishikawa, and H. Ishida
Enhancement by Epinephrine of Benzylpenicillin Transport in Rat Small Intestine
J. Pharmacol. Exp. Ther., April 1, 2000; 293(1): 128 - 135.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
L. Liu and I. M. Coupar
Involvement of Alpha-2 Adrenoceptors in the Effects of Moxonidine on Intestinal Motility and Fluid Transport
J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1367 - 1374.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1990 by the American Society for Pharmacology and Experimental Therapeutics.